2Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal Cancer:a muhicentre randomiscd trial [ J ].Lancet,2000,355(9209):1041-1047.
3Zhou CF,Ma T,Su Y,et al.UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal Cancer [ J ].Anticancer Agents Med Chem,2013,13(2):235-241.
4Toffoli G,Cecchin E,Corona G,et al.Pharmacogenetics of irinotecan [ J ].Curr Med Chem Anticancer Agents,2003,3(3):225-237.
5Hirose K,Kozu C,Yamashita K,et al.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal Cancer and wild-type UGT1A1 gene [ J ].Oncol Lett,2012,3(3):694-698.
6Massacesi C,Terrazzino S,Marcucci F,et al.Uridine diphosphate glucuronosyl transferase 1A 1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy [ J ].Cancer,2006,106(5):1007-1016.
7Kaniwa N,Kurose K,Jinno H,et al.Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T(P229L)found in an African-American [ J ].Drug Metab Dispos,2005,33(3):458-465.
8Hazama S,Mishima H,Tsunedomi R,et al.UGT1A1*6,1A7*3,and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic eolorectal cancer in two prospective studies in Japan [ J ].Cancer Sci,2013,104(12):1662-1669.
9Inoue K,Sonobe M,Kawamura Y,et al.Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in Cancer patients receiving irinotecan-based chemotherapy [ J ].Tohoku J Exp Med,2013,229(2):107-114.
10Kadakol A,Ghosh SS,Sappal BS,et al.Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase(UGT1A1)causing Crigler-Najjar and Gilbert syndromes:correlation of genotype to phenotype [ J ].Hum Mutat,2000,16(4):297-306.
